Clinical Trials

572 enrolled

Phase 3 Active not recruiting

Stomach Neoplasms

NCT07371910 2026-01-28

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

200 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT05198609 2026-01-21

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

214 enrolled

Carcinoma, Hepatocellular

NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

550 enrolled

Stomach Neoplasms

NCT07314203 2026-01-02

SOP-XH-IRB

118 enrolled

Phase 3 Active not recruiting

Stomach Neoplasms

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

687 enrolled

Carcinoma, Hepatocellular

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

885 enrolled

Stomach Neoplasms

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

200 enrolled

Fludzoparib" and Anti-angiogenic

NCT05613478 2024-12-31

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

130 enrolled

Carcinoma, Hepatocellular

NCT06539091 2024-08-06

Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

51 enrolled

Carcinoma, Ovarian Epithelial

NCT06438627 2024-07-16

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

164 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06447623 2024-06-07

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

184 enrolled

Advanced Breast Cancer

NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

543 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT02329860 2024-01-22

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

400 enrolled 13 charts

Carcinoma, Hepatocellular

NCT06188455 2024-01-03

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

37 enrolled

Ovarian Neoplasms

NCT04714190 2023-12-21

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

351 enrolled

Stomach Neoplasms

NCT05889871 2023-06-05

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

916 enrolled

HR+/HER2-breast Cancer

NCT05854849 2023-05-11

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

244 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT03048877 2023-04-12

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

118 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04229615 2022-04-25

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

690 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05049681 2021-09-20

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

234 enrolled

Esophageal Neoplasms

NCT04490421 2021-02-08

Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.

45 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04296370 2020-08-10

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

474 enrolled

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

NCT04203485 2020-05-08

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

762 enrolled

PD-L1 Positive Non-small Cell Lung Cancer

NCT04000295 2019-10-08

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

280 enrolled

Ovarian Neoplasms

NCT03889626 2019-03-26

The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

242 enrolled

Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Diseases, Stomach Neoplasms

NCT03651219 2018-08-29

Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

90 enrolled

Small Cell Lung Carcinoma

NCT03598348 2018-07-26

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

288 enrolled

Stomach Neoplasms

NCT03355612 2017-11-28

XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

456 enrolled

Stomach Neoplasms

NCT03100955 2017-04-04

A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

120 enrolled

Progression Free Survival

NCT02332512 2017-02-24

ANSWER

417 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01512745 2016-10-17

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

267 enrolled 11 charts

Stomach Neoplasms

NCT02537171 2016-08-02

Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer

40 enrolled

Stomach Neoplasms

NCT02824458 2016-07-07

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

246 enrolled

EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

NCT01287962 2013-12-09

Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

480 enrolled